NVO News

Novo Nordisk's Ozempic® pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US

What the U.S. Pharmaceutical Industry Could Learn from How Africa Solves Patient Access

WEBINAR INVITATION: Novo Resources Corp. Executive Co-Chairman to discuss the March Quarter Activities and Outlook

Novolog or Novomix or NovoRapid (Novo Nordisk) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM USA - English USA - English

Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

Novo Nordisk A/S: Denecimig (Mim8) significantly reduced annualised bleeding rate in people with haemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

Novo Resources Provides Business Update

SPROUT PHARMACEUTICALS, MAKERS OF ADDYI (FLIBANSERIN), NAMED ONE OF THE 10 MOST INFLUENTIAL HEALTH AND LIFE SCIENCE COMPANIES OF 2026 BY TIME

Penn Dental Medicine Study Investigates Plant-encapsulated Delivery Platform for Oral Delivery of GLP-1 Drugs